Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression. Approximately 25% of patients diagnosed with triple negative breast cancer carry a germline BRCA1 or BRCA2 mutation. They ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Barchiesi, Giacomo, Roberto, Michela, Verrico, Monica, Vici, Patrizia, Tomao, Silverio, Tomao, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655309/
https://www.ncbi.nlm.nih.gov/pubmed/34900718
http://dx.doi.org/10.3389/fonc.2021.769280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655309/
https://www.ncbi.nlm.nih.gov/pubmed/34900718
http://dx.doi.org/10.3389/fonc.2021.769280

Ejemplares similares